Morepen Laboratories Limited Share Price & Analysis

Morepen Labs reports Q1 FY26 financial results

*Morepen Labs reports Q1 FY26 financial results.* The company released its financial performance for the quarter ended June 30, 2026, via a newspaper publication. Key metrics like revenue, profit, and margins will be closely analyzed by traders for guidance and future outlook. **Earnings announcement may trigger volatility in the counter.** 📊 *STOCKS:* $MOREPENLAB | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Earnings

Morepen reports record Q1 revenue, EBITDA up 207%, PAT up 394%

*Morepen reports record Q1 revenue, EBITDA up 207%, PAT up 394%*. The company posted its highest-ever quarterly revenue and earnings in Q1 FY27. EBITDA surged by **207%** while PAT jumped **394%** year-on-year. Its CDMO segment has entered full-scale commercialization, marking a key growth milestone. 📊 *STOCKS:* $MOREPENLAB | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Earnings

Morepen Labs reports Q1 FY26 financial results

*Morepen Labs reports Q1 FY26 financial results.* The company announced its financial performance for the quarter ended June 30, 2026. Results were submitted to the stock exchange as part of mandatory corporate disclosure. No major deviations or surprises were indicated in the filing. 📊 *STOCKS:* $MOREPENLAB | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Earnings

Morepen starts commercial supplies under ₹825 Cr CDMO mandate

*Morepen starts commercial supplies under ₹825 Cr CDMO mandate.* The company has commenced commercial-scale deliveries under a **₹825 crore** CDMO agreement, marking a key milestone in its contract development and manufacturing business. This order strengthens its revenue visibility and operational scale in the pharma export segment. 📊 *STOCKS:* MOREPENLAB | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #CDMO

Morepen Labs shares no impact from annual report web link notice

*Morepen Labs shares no impact from annual report web link notice*. The company informed exchanges about a letter to members without registered email IDs, providing a weblink to the **Annual Report 2025-26**. This is a routine corporate filing with no financial or operational implications. No material impact expected on stock price or trading activity. 📊 *STOCKS:* $MOREPENLAB | 🏢 *SECTOR:* Pharma | #LOWIMPACT #AnnualReport

Morepen Laboratories to hold shareholders meeting

*Morepen Laboratories to hold shareholders meeting.* The company has announced a gathering of its shareholders, as per a regulatory filing. Such meetings are routine and typically address administrative or governance matters. No financial impact is expected from this event. 📊 *STOCKS:* MOREPENLAB | 🏢 *SECTOR:* Pharma | #LOWIMPACT #ShareholdersMeeting

Morepen Labs declares dividend, sets AGM date

*Morepen Labs announces dividend and 41st Annual General Meeting details.* The record date has been set for **July 15, 2024**, with AGM scheduled on **July 20, 2024**. Dividend payout and meeting agenda detailed in newspaper publication. Investors should note key dates for entitlements and participation. 📊 *STOCKS:* $MOREPENLAB | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Dividend

Morepen Laboratories issues general corporate updates

*Morepen Laboratories issues general corporate updates.* The company filed routine disclosures with the NSE on September 26, 2026. No **financial figures** or **strategic changes** were disclosed. The update does not indicate any immediate business or operational shift. 📊 *STOCKS:* $MOREPENLAB | 🏢 *SECTOR:* Pharma | #LOWIMPACT #corporate

Morepen Labs sets final dividend record date

*Morepen Labs sets final dividend record date.* The company has announced **19-Sep-2026** as the record date for final dividend disbursement. Shareholders registered on this date will be eligible for the payout. The dividend amount and declaration date were not specified in this filing. 📊 *STOCKS:* $MOREPENLAB | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Dividend

Morepen Labs shares unchanged after investor presentation

*Morepen Laboratories Limited held an investor presentation with no major announcements.* The stock remained flat as no financial updates or guidance changes were provided. The presentation focused on company overview and business segments without revealing new data. 📊 *STOCKS:* MOREPENLAB | 🏢 *SECTOR:* Pharma | #LOWIMPACT #InvestorPresentation